Skip to main content
SpringerLink
Log in

A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

The immunohistochemnichally determined receptor status, as well as first-generation risk factors (tumor size, lymph node status, histologic grading including subfactors, tumor histology, and biochemically determined receptor status) were prospectively analyzed in 288 cases of primary breast cancer for their impact on recurrence-free survival (RFS) and overall survival (OS) after a median observation period of 41 months.

Immunohistochemically (ER-ICA) and biochemically determined estrogen receptors (ER-DCC), as well as tumor size, lymph node status, histologic grading, mitotic rate, and nuclear polymorphism, were of prognostic value for recurrence-free survival and/or overall survival.

In multivariate analysis, lymph node status, tumor size, and mitotic rate proved to be independent prognosticators; ER-ICA showed significance in the univariate analysis which dropped, however, when multivariate analysis was applied.

The prognostic power of histologic grading in our series seemed to depend mainly on the subfactors which relate to nuclear features.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Early Breast Cancer Trialist's Colloborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339: 1–15, 71-85, 1992

    Google Scholar 

  2. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884–2888, 1980

    Google Scholar 

  3. Kinne DW, Ashikari R, Butler A, Menendez-Botet C, Rosen PP, Schwartz M: Estrogen receptor protein in breast cancer as a predictor of recurrence. Cancer 47: 2364–2367, 1981

    Google Scholar 

  4. Chevallier B, Meintzmann F, Mosseri Vet al.: Prognostic value of estrogen and progesterone receptors in operable breast cancer: results of a univariate and multivariate analysis. Cancer 62: 2517–2524, 1988

    Google Scholar 

  5. Hilf R, Feldstein ML, Savlov ED, Gibson SL, Seneca B: The lack of relationship between estrogen receptor status and response to chemotherapy. Cancer 46: 2797–2800, 1980

    Google Scholar 

  6. Sears HF, Janus C, Levy W, Hopson R, Creech R: Breast cancer without axillary metastases: Are there high risk biologic subpopulations? Cancer 50: 1820–1827, 1982

    Google Scholar 

  7. Shapiro CM, Schiffeling P, Bitran JDet al.: Prognostic value of the estrogen receptor value in pathologic stage I and II adenocarcinoma of the breast. J Surg Oncol 19:119–121, 1982

    Google Scholar 

  8. Clark GM, McGuire WL: Progesterone receptors and human breast cancer. Breast Cancer Res Treat 3:157–163, 1983

    Google Scholar 

  9. Vollenweider-Zerargui L, Barrelet L, Wong Y, LeMarchand-Beraud T, Gomez F: The predictive value of estrogen and progesterone receptor concentrations on the clinical behaviour of breast cancer in women. Cancer 57: 1171–1180, 1986

    Google Scholar 

  10. Alanko A, Heinonen E, Scheinin T, Tolppanen EM, Vihko R: Estrogen and progesterone receptors and disease free interval in primary breast cancer. Br J Cancer 50: 667–672, 1984

    Google Scholar 

  11. Thorpe SM, Rose C, Rasmussen BBet al.: Steroid hormone receptors as prognostic indicators in primary breast cancer. Breast Cancer Res Treat (Suppl.) 7: 91–98, 1986

    Google Scholar 

  12. Greene GL, Fitch FW, Jensen EV: Monoclonal antibodies to estrophilin: Probes for the study of estrogen receptors. Proc Natl Acad Sci USA 77: 157–161, 1980

    Google Scholar 

  13. Perrot-Applanat M, Logeat F, Croyer-Picard MT, Milgrom E: Immunocytochemical study of mammalian progesterone receptor using monoclonal antibodies. Endocrinology 116: 1473–1483, 1985

    Google Scholar 

  14. Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R: Immunocytochemical localization of estrogen and progesterone receptors and prognosis in human primary breast cancer. Cancer Res 50: 7057–7061, 1990

    Google Scholar 

  15. Pertschuk LP, Feldman JG, Eisenberg KBet al.: Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal antibody. Cancer 62: 342–349, 1988

    Google Scholar 

  16. Pertschuk LP, Kim DS, Nayer Ket al.: Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Cancer 66: 1663–1670, 1990

    Google Scholar 

  17. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarthy Jr, KS: Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: Comparison with quantitative biochemical methods. Cancer Res 49: 1052–1056, 1989

    Google Scholar 

  18. DeSombre ER, Thorpe SM, Rose Cet al.: Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. Cancer Res (Suppl) 40: 4256–4264, 1986

    Google Scholar 

  19. Gottardi O, Baiocchi C, Ferrari Met al.: Correlation between histochemically assessed hormonal receptor content and clinical course in breast cancer. Oncology 48: 221–225, 1991

    Google Scholar 

  20. Bloom HJG, Richardson WW: Histological grading and prognosis in breast carcinoma. Br J Cancer 11: 359–377, 1957

    Google Scholar 

  21. Stierer M, Rosen H, Weber R: Nuclear pleomorphism, a strong prognostic factor in axillary node negative small invasive breast cancer. Breast Cancer Res Treat 20: 109–116, 1991

    Google Scholar 

  22. Stierer M, Rosen HR, Weber R, Marczell A, Kornek GV, Czerwenka E: Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter. Surg Gynecol Obst 175: 151–160, 1992

    Google Scholar 

  23. UICC (International Union against Cancer). TNM classification of malignant tumors (3rd ed.). Geneva: UICC, 4754, 1979

    Google Scholar 

  24. WHO: The World Health Organization histological typing of breast tumors (2nd ed.). Am J Clin Pathol 78: 806–816, 1982

    Google Scholar 

  25. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow-up. Histopathology 19: 403–410, 1991

    Google Scholar 

  26. Bässler R, Böcker W, Hermanek Det al.: Die gegenwärtige Situation des Gradings beim Mammakarzinom. Pathologie 13: 130–134, 1992

    Google Scholar 

  27. EORTC Breast Cancer Cooperative Group: Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer Clin Oncol 16: 1513–1515, 1980

    Google Scholar 

  28. Remmele W, Stegner HE: Vorschlag zur einheitlichen Definition eines immunreaktiven Score (IRS) für den immunhistochemischen Östrogenrezeptornachweis (ER-ICA) im Mammakarzinomgewebe. Pathologie 8: 138–140, 1987

    Google Scholar 

  29. Stierer M, Rosen HR: Influence of early diagnosis on prognosis of recurrent breast cancer. Cancer 64: 1128–1131, 1989

    Google Scholar 

  30. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958

    Google Scholar 

  31. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163–170, 1966

    Google Scholar 

  32. Peto R, Pike MD, Armitage Pet al.: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 34: 585–612, 1976

    Google Scholar 

  33. Cox DR: Regression models and life tables. JR Stat Soc (B) 34: 187–220, 1972

    Google Scholar 

  34. Rosen PP, Groshen S, Saigo PEet al.: A long term follow up study of survival in stage I (TIN0M0) and stage II (TIN0M0) breast carcinoma. J Clin Oncol 7: 355–366, 1989

    Google Scholar 

  35. Carter CL, Allen D, Henson DE: Relation of tumor size, lymph node status and survival in 24740 breast cancer cases. Cancer 63: 181–187, 1989

    Google Scholar 

  36. Valagussa P, Bonadonna G, Veronesi U: Pattern of relapse and survival following radical mastectomy. Cancer 41: 1170–1178, 1978

    Google Scholar 

  37. Rank F, Dombernowsky P, Bang Jesperson NCet al.: Histologic malignancy grading of invasive ductal breast carcinoma. A regression analysis of prognostic factors in low-risk carcinoma from a multicenter trial. Cancer 60: 1299–1305

  38. LeDoussal V, Tubiana-Hulin M, Friedman Set al.: Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64: 1914–1921, 1989

    Google Scholar 

  39. Alanko A, Heinonen E, Scheinin T, Tolppanen EM, Vihko R: Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer 56: 1696–1700, 1985

    Google Scholar 

  40. Rose C, Mouridsen HT, Thorpe SM, Andersen J, Blichert-Toft AL, Andersen KW: Anti-estrogen treatment of postmenopausal breast cancer patients with high risk of recurrence: Seventy-two months of life-table analysis and steroid hormone receptor status. World J Surg 98: 765–774, 1985

    Google Scholar 

  41. Fisher ER: Prognostic and therapeutic significance of pathological features of breast cancer. NCI Monogr 1: 29–34, 1986

    Google Scholar 

  42. Davies BW, Gelber RD, Goldhirsh Aet al.: Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer 58: 2662–2670, 1986

    Google Scholar 

  43. Thorpe SM, Rose C, Rasmussen BB, Mouridsen HT, Bayer T, Keiding N (for the Danish Breast Cancer Cooperative Group): Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer. Cancer Res 47: 6126–6133, 1987

    Google Scholar 

  44. Komitowksy D, Janson C: Quantitative features of chromatin structure in the prognosis of breast cancer. Cancer 65: 2725–2730, 1990

    Google Scholar 

  45. Dixon JM, Page DL, Anderson TJet al.: Long term survivors after breast cancer. Br J Surg 72: 445–448, 1985

    Google Scholar 

  46. Rapin V, Contesso G, Mouriesse Het al.: Medullary breast carcinoma. A re-evaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 61: 2503–2510, 1988

    Google Scholar 

  47. Howell A, Harris M: Infiltrating lobular carcinoma of the breast. Br Med J 291: 1371–1376, 1985

    Google Scholar 

  48. Page DL, Anderson TJ: Diagnostic Histopathology of the Breast. Endinburgh, Churchill Livingstone, 1987

    Google Scholar 

  49. Stierer M, Rosen H, Weber R, Hanak H, Spona J, Tüchler H: Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer: Correlation of histopathology and prognostic factors. Ann Surg 218: 13–21, 1993

    Google Scholar 

  50. Reiner A, Reiner G, Spona J, Schemper M, Holzner H: Histopathologic characterization of human breast cancer in correlation with estrogen receptor status. Cancer 61: 1149–1154, 1988

    Google Scholar 

  51. McGuire WL, Dressler LG: Emerging impact of flow cytometry in predicting recurrence and survival in breast cancer patients. J Natl Cancer Inst 75: 405–410, 1985

    Google Scholar 

  52. Sigurdsson H, Baldetorp B, Borg Aet al.: Indicators of prognosis in node negative breast cancer. N Engl J Med 322: 1045–1053, 1990

    Google Scholar 

  53. Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL: Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297–302, 1990

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Hanusch Medical Center, Vienna, Austria

    Michael Stierer & Leo Auerbach

  2. Department of Surgery, Donauspital, Vienna, Austria

    Harald Rosen

  3. Department of Pathology-Histology, Hanusch-Krankenhaus, Vienna, Austria

    Renate Weber & Hanns Hanak

  4. Ludwig Boltzmann-Institut for Experimental Endocrinology, Endocrinol. Laboratory, University of Vienna, Austria

    Jürgen Spona

  5. Ludwig Boltzmann-Institut for Leukemia Research and Hematology, Hanusch-Krankenhaus, Vienna, Austria

    Heinz Tüchler

Authors
  1. Michael Stierer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harald Rosen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Renate Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hanns Hanak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Leo Auerbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jürgen Spona
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Heinz Tüchler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stierer, M., Rosen, H., Weber, R. et al. A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer. Breast Cancer Res Tr 36, 11–21 (1995). https://doi.org/10.1007/BF00690180

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00690180

Key words

Search

Navigation